<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748147</url>
  </required_header>
  <id_info>
    <org_study_id>2016-4435</org_study_id>
    <nct_id>NCT03748147</nct_id>
  </id_info>
  <brief_title>Cervical Ripening in Obese Women: Efficacy of 25 mcg Versus 50 mcg of Misoprostol</brief_title>
  <official_title>Cervical Ripening in Obese Women: a Prospective, Randomized Trial Comparing Efficacy of 25 mcg Versus 50 mcg of Misoprostol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective clinical trial to determine if 50 mcg versus 25 mcg po every four hours
      of misoprostol has improved efficacy and similar safety in obese women undergoing cesarean
      section.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will perform a prospective, randomized, double-blind clinical trial with parallel
      assignment.

      Obese women (delivery BMI 30 or more) who agree to participation will be randomly designated
      to receive either 25 mcg po q 4 hour (control) misoprosol versus 50 mcg po q 4 hours. Our
      primary outcome will be the rate of successful induction. Secondary outcomes will include
      ability to achieve a Bishop score greater than 7, time to active labor, and safety data
      including rate of tachysystole, non-reassuring fetal status, NICU admission.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Parallel design randomized trial. Two study groups: control (25 mcg) intervention (50 mcg)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Both arms will receive identical appearing drug made by the Investigational Drug Unit of the Pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal delivery</measure>
    <time_frame>Variable, but within 4 days</time_frame>
    <description>Successful induction defined as a vaginal delivery following labor induction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completed cervical ripening</measure>
    <time_frame>2 days</time_frame>
    <description>Bishop score of greater than 7 (Bishop score designated per protocol based upon cervical dilation, effacement, station, consistency and position).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific time interval from start of induction to active labor</measure>
    <time_frame>2 days</time_frame>
    <description>We will measure the interval (hours) between start of cervical ripening and active labor defined as reaching a cervical dilation of 6 cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of tachysystole, fetal nonreassuring status, uterine rupture</measure>
    <time_frame>3 days</time_frame>
    <description>Rate of the following as categorical variables: tachysystole (any delay in study medication administration for greater than 5 contractions/10 minute window), non-reassuring fetal status (any evaluation of the fetal tracing that leads to delays in study drug administration secondary to concerns for the fetal status), NICU admission, uterine rupture</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care, misoprostol 25 mcg po every four hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Misoprostol 50 mcg po every four hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>prostaglandin e1</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Labor induction, BMI of 30 or greater, English speaking

        Exclusion Criteria:

          -  Prior cesarean section, uterine tachysystole (5 contractions/ 10 minutes) on
             admission, Contraindication to labor induction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnancy, Study of labor induction</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carri R Warshak, M.D.</last_name>
    <phone>513-558-8448</phone>
    <email>eaglercr@ucmail.uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David McKinney, M.D.</last_name>
    <phone>513-558-8448</phone>
    <email>mckinndi@ucmail.uc.edu</email>
  </overall_contact_backup>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Carri Warshak</investigator_full_name>
    <investigator_title>Associate Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Would consider upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

